Protagonist Therapeutics (PTGX) Reports Q1 Loss, Tops Revenue Estimates

Group 1 - Protagonist Therapeutics reported a quarterly loss of $0.19 per share, significantly better than the Zacks Consensus Estimate of a loss of$0.50, representing an earnings surprise of 62% [1] - The company posted revenues of $28.32 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 149.90$254.95 million [2] - Protagonist Therapeutics shares have increased by approximately 14.7% since the beginning of the year, contrasting with the S&P 500's decline of -3.9% [3] Group 2 - The current consensus EPS estimate for the upcoming quarter is -$0.56 on revenues of$11.33 million, and for the current fiscal year, it is -$1.23 on revenues of$97.8 million [7] - The Medical - Biomedical and Genetics industry, to which Protagonist Therapeutics belongs, is currently ranked in the top 31% of over 250 Zacks industries, indicating a favorable outlook [8]